Streetbeat News

FREQ

Frequency Therapeutics Inc

Employees

Industry

Pharmaceutical Preparation Manufacturing

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.

Open

0.29

Mkt cap

11M

Volume

309K

High

0.32

P/E Ratio

-0.16

52-wk high

5.59

Low

0.28

Div yield

N/A

52-wk low

0.18

In Friday's after-market session, several health care stocks experienced significant movement. Cadrenal Therapeutics, Vivos Therapeutics, BridgeBio Pharma, Assembly Biosciences, Vincerx Pharma, and AIM ImmunoTech saw gains, while Virios Therapeutics, Minerva Surgical, Anitra, Frequency Therapeutics, OpGen, and BioVie experienced losses.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 9:38 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. Gainers included Frequency Therapeutics (FREQ), Nutriband (NTRB), Biodexa Pharmaceuticals (BDRX), Ainos (AIMD), Redhill Biopharma (RDHL), and Monopar Therapeutics (MNPR). Losers included Theseus Pharmaceuticals (THRX), Caribou Biosciences (CRBU), Rockwell Medical (RMTI), Yield10 Bioscience (YTEN), Vivos Therapeutics (VVOS), and Healthcare Triangle (HCTI).

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 5:37 pm

The article lists the stocks that gained and lost the most in Friday's mid-day session. Among the gainers, PainReform Ltd. (PRFX) shares climbed 103% after announcing pricing of a $2.7 million concurrent registered direct offering and private placement. Frequency Therapeutics, Inc. (FREQ) gained 41.7% after agreeing to merge with Korro Bio. Among the losers, Theseus Pharmaceuticals, Inc. (THRX) shares dipped 69.9% after discontinuing enrollment in Phase 1/2 study and terminating development of THE-630 for gastrointestinal stromal tumors. State Street Corporation (STT) fell 10.5% after reporting slightly worse-than-expected second-quarter revenues and an increase in total expenses.

Portfolio Pulse from Lisa Levin

July 14, 2023 | 4:54 pm

US stocks traded higher with Dow Jones gaining over 100 points. Citigroup reported better-than-expected Q2 results with a net revenue of $19.44 billion, beating the consensus of $19.27 billion. Aehr Test Systems, Frequency Therapeutics, and ACADIA Pharmaceuticals saw their shares rise after positive news, while Theseus Pharmaceuticals, Galmed Pharmaceuticals, and Leslie's saw their shares drop due to negative developments. Crude oil traded down 2%.

Portfolio Pulse from Lisa Levin

July 14, 2023 | 4:13 pm

Frequency Therapeutics Inc (NASDAQ:FREQ) and Korro Bio Inc have announced an all-stock merger. Frequency Therapeutics has discontinued its remyelination program for Multiple Sclerosis and is exploring strategic alternatives. If the program is not monetized before the merger, Frequency Therapeutics stockholders will be issued a contingent value right for each outstanding share. The combined company will focus on advancing Korro Bio's RNA editing programs and will trade on Nasdaq under the ticker symbol 'KRRO'. The merger is expected to close in Q4 2023.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:22 pm

During Friday's pre-market session, several health care stocks experienced significant movements. Ainos, Frequency Therapeutics, Nutriband, Monopar Therapeutics, Mallinckrodt, and OKYO Pharma saw increases in their stock prices, while Theseus Pharmaceuticals, Petros Pharma, Caribou Biosciences, PAVmed, MSP Recovery, and Veradigm experienced decreases.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:12 pm

Frequency Therapeutics has agreed to merge with Korro Bio in an all-stock transaction. This has led to an increase in Frequency Therapeutics' share prices.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 11:14 am

Korro Bio and Frequency Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction. The combined company will focus on the advancement of Korro Bio's portfolio of RNA editing programs and will operate under Korro Bio, Inc. It will apply to trade on Nasdaq under the ticker symbol 'KRRO'.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 10:32 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.